Get more info

Get more information
on LUCENTIS:
1-866-LUCENTIS
(1-866-582-3684)
Monday-Friday
8AM-9PM (EST)

 

   

Terms and Conditions

By using this site you acknowledge that Genentech, Inc. is providing the material for informational purposes only and that neither Genentech, Inc. nor their licensors are providing the materials to you for the purposes of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials, and Genentech, Inc. and their licensors strongly urge that you consult with a physician in connection with any and all treatment options that may be available to you.

This site could contain technical inaccuracies and/or typographical errors. Genentech, Inc. may make improvements and/or changes in the materials contained on the site at any time.

In no event shall Genentech, Inc. or their licensors be liable for any direct, special, indirect, incidental or consequential damages or any damages whatsoever resulting from loss related to the use of our Web sites, whether in an action of contract, breach of warranty, negligence, or other tortious action arising out of or in connection with the use of the materials contained on this site.


Who is LUCENTIS for?


LUCENTIS® (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (AMD).


Important LUCENTIS Safety Information


Like any prescription medication, LUCENTIS is not for everyone. You should not use LUCENTIS if you have an infection in or around the eye.


Like other injections given into the eye, serious eye infection (endophthalmitis) and detached retina have occurred with LUCENTIS. Increases in eye pressure have been seen within 1 hour of an injection. Your eye doctor should monitor your eye pressure and eye health during the week after the injection. If your eye becomes red, sensitive to light, painful, or has a change in vision, you should seek immediate care from your eye doctor.


Although uncommon, conditions associated with eye- and non–eye-related blood clots (arterial thromboembolic events) may occur.


Serious side effects related to the injection procedure were rare. These included serious eye infection, detached retina, and cataract. Other uncommon serious side effects included inflammation inside the eye and increased eye pressure.


The most common eye-related side effects were red eye, eye pain, small specks in vision, the feeling that something is in your eye, and increased tears. The most common non–eye-related side effects were high blood pressure, nose and throat infection, and headache.


LUCENTIS is for prescription use only.

Individual results with LUCENTIS may vary.


Please see LUCENTIS full Prescribing Information.